Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Advances in the extracellular vesicles treatment of alopecia

Wu X., Tang S.

Clinical Trial on Hair Loss, published in Ann Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Ann Med (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40768606
PMCID
PMC12329855
DOI
10.1080/07853890.2025.2543517
Citations
3

Abstract (original English)

Background Alopecia is a prevalent condition that significantly impacts appearance, mental health, and overall quality of life. Current clinical treatments for alopecia include medication, hair transplantation, low-level light therapy, and stem cell therapy, among others. However, the effectiveness of these treatments remains far from ideal. Extracellular vesicles (EVs) have emerged as a promising therapeutic strategy, yet challenges, such as mass production and clinical application persist. This review aims to explore recent advancements in the use of EVs for the treatment of alopecia. Methods A comprehensive literature search was conducted in the PubMed database using a range of relevant keywords: extracellular vesicles, alopecia, hair loss, preparation, exosomes, microvesicles, apoptotic bodies, nanoscale particles, preclinical studies, clinical trial, clinical transformation, regenerative medicine, tissue engineering, stem cell, bioactive molecules, and extraction methods. The papers mostly focus on the biological characteristics and preparation of EVs, the basic and clinical research of EVs in the treatment of hair loss, and the challenges of clinical transformation of EVs were retracted. Results EVs are nanoscale, spherical particles enclosed by a lipid bilayer. They exert their effects by activating signaling pathways through ligand binding or by entering cells via membr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansAlopeciaRegenerative MedicineExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research